November 27-29 2018
Cambridge, MA, USA

 

With almost 45% of all deaths in the developed world believed to be attributable to chronic fibroproliferative disease, pathological fibrosis is becoming increasingly recognised as a huge unmet medical need. Whilst clinical breakthroughs and successful results mean anti-fibrotics for NASH, IPF and CKD could be around the corner; there remains multiple challenges in anti-fibrotic drug development and a lack of arsenal against curatively slowing or reversing fibrosis.

The 2nd Anti-Fibrotic Drug Development Summit fills the gap as the only industry-dedicated forum for drug developers focused on organ-specific indications to participate in cross-disciplinary, multi-organ discussion and take away new insights into anti-fibrotic drug development research including:

  • Mechanisms of action and new targets for emerging candidates; alongside updates on leading advancements targeting integrins and TGFβ
  • Innovations in preclinical modalities to improve the clinical relevancy of engineered in vitro tissues and recapitulation of human disease in vivo
  • Applying genomics to inform clinical trial design and better understand population heterogeneity

Built from research with 20 of the leading experts in immuno-inflammation and fibrosis; the 2nd Anti-Fibrotic Drug Development Summit will enable you to evaluate key challenges in translating fibrotic mechanisms into clinically effective therapeutics with a tighter lens.

"Excellent opportunity to catch up with the field, hear other industry speakers present their work"

Genentech

"Valuable to talk with other companies about approaches to challenging issues"

Merck

Media Partner